Cargando…
Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing
Next generation sequencing (NGS) is a trending new standard for genotypic HIV-1 drug resistance (HIVDR) testing. Many NGS HIVDR data analysis pipelines have been independently developed, each with variable outputs and data management protocols. Standardization of such analytical methods and comparis...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994664/ https://www.ncbi.nlm.nih.gov/pubmed/32005884 http://dx.doi.org/10.1038/s41598-020-58544-z |
_version_ | 1783493240983388160 |
---|---|
author | Lee, Emma R. Parkin, Neil Jennings, Cheryl Brumme, Chanson J. Enns, Eric Casadellà, Maria Howison, Mark Coetzer, Mia Avila-Rios, Santiago Capina, Rupert Marinier, Eric Van Domselaar, Gary Noguera-Julian, Marc Kirkby, Don Knaggs, Jeff Harrigan, Richard Quiñones-Mateu, Miguel Paredes, Roger Kantor, Rami Sandstrom, Paul Ji, Hezhao |
author_facet | Lee, Emma R. Parkin, Neil Jennings, Cheryl Brumme, Chanson J. Enns, Eric Casadellà, Maria Howison, Mark Coetzer, Mia Avila-Rios, Santiago Capina, Rupert Marinier, Eric Van Domselaar, Gary Noguera-Julian, Marc Kirkby, Don Knaggs, Jeff Harrigan, Richard Quiñones-Mateu, Miguel Paredes, Roger Kantor, Rami Sandstrom, Paul Ji, Hezhao |
author_sort | Lee, Emma R. |
collection | PubMed |
description | Next generation sequencing (NGS) is a trending new standard for genotypic HIV-1 drug resistance (HIVDR) testing. Many NGS HIVDR data analysis pipelines have been independently developed, each with variable outputs and data management protocols. Standardization of such analytical methods and comparison of available pipelines are lacking, yet may impact subsequent HIVDR interpretation and other downstream applications. Here we compared the performance of five NGS HIVDR pipelines using proficiency panel samples from NIAID Virology Quality Assurance (VQA) program. Ten VQA panel specimens were genotyped by each of six international laboratories using their own in-house NGS assays. Raw NGS data were then processed using each of the five different pipelines including HyDRA, MiCall, PASeq, Hivmmer and DEEPGEN. All pipelines detected amino acid variants (AAVs) at full range of frequencies (1~100%) and demonstrated good linearity as compared to the reference frequency values. While the sensitivity in detecting low abundance AAVs, with frequencies between 1~20%, is less a concern for all pipelines, their specificity dramatically decreased at AAV frequencies <2%, suggesting that 2% threshold may be a more reliable reporting threshold for ensured specificity in AAV calling and reporting. More variations were observed among the pipelines when low abundance AAVs are concerned, likely due to differences in their NGS read quality control strategies. Findings from this study highlight the need for standardized strategies for NGS HIVDR data analysis, especially for the detection of minority HIVDR variants. |
format | Online Article Text |
id | pubmed-6994664 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-69946642020-02-06 Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing Lee, Emma R. Parkin, Neil Jennings, Cheryl Brumme, Chanson J. Enns, Eric Casadellà, Maria Howison, Mark Coetzer, Mia Avila-Rios, Santiago Capina, Rupert Marinier, Eric Van Domselaar, Gary Noguera-Julian, Marc Kirkby, Don Knaggs, Jeff Harrigan, Richard Quiñones-Mateu, Miguel Paredes, Roger Kantor, Rami Sandstrom, Paul Ji, Hezhao Sci Rep Article Next generation sequencing (NGS) is a trending new standard for genotypic HIV-1 drug resistance (HIVDR) testing. Many NGS HIVDR data analysis pipelines have been independently developed, each with variable outputs and data management protocols. Standardization of such analytical methods and comparison of available pipelines are lacking, yet may impact subsequent HIVDR interpretation and other downstream applications. Here we compared the performance of five NGS HIVDR pipelines using proficiency panel samples from NIAID Virology Quality Assurance (VQA) program. Ten VQA panel specimens were genotyped by each of six international laboratories using their own in-house NGS assays. Raw NGS data were then processed using each of the five different pipelines including HyDRA, MiCall, PASeq, Hivmmer and DEEPGEN. All pipelines detected amino acid variants (AAVs) at full range of frequencies (1~100%) and demonstrated good linearity as compared to the reference frequency values. While the sensitivity in detecting low abundance AAVs, with frequencies between 1~20%, is less a concern for all pipelines, their specificity dramatically decreased at AAV frequencies <2%, suggesting that 2% threshold may be a more reliable reporting threshold for ensured specificity in AAV calling and reporting. More variations were observed among the pipelines when low abundance AAVs are concerned, likely due to differences in their NGS read quality control strategies. Findings from this study highlight the need for standardized strategies for NGS HIVDR data analysis, especially for the detection of minority HIVDR variants. Nature Publishing Group UK 2020-01-31 /pmc/articles/PMC6994664/ /pubmed/32005884 http://dx.doi.org/10.1038/s41598-020-58544-z Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Lee, Emma R. Parkin, Neil Jennings, Cheryl Brumme, Chanson J. Enns, Eric Casadellà, Maria Howison, Mark Coetzer, Mia Avila-Rios, Santiago Capina, Rupert Marinier, Eric Van Domselaar, Gary Noguera-Julian, Marc Kirkby, Don Knaggs, Jeff Harrigan, Richard Quiñones-Mateu, Miguel Paredes, Roger Kantor, Rami Sandstrom, Paul Ji, Hezhao Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing |
title | Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing |
title_full | Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing |
title_fullStr | Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing |
title_full_unstemmed | Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing |
title_short | Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing |
title_sort | performance comparison of next generation sequencing analysis pipelines for hiv-1 drug resistance testing |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994664/ https://www.ncbi.nlm.nih.gov/pubmed/32005884 http://dx.doi.org/10.1038/s41598-020-58544-z |
work_keys_str_mv | AT leeemmar performancecomparisonofnextgenerationsequencinganalysispipelinesforhiv1drugresistancetesting AT parkinneil performancecomparisonofnextgenerationsequencinganalysispipelinesforhiv1drugresistancetesting AT jenningscheryl performancecomparisonofnextgenerationsequencinganalysispipelinesforhiv1drugresistancetesting AT brummechansonj performancecomparisonofnextgenerationsequencinganalysispipelinesforhiv1drugresistancetesting AT ennseric performancecomparisonofnextgenerationsequencinganalysispipelinesforhiv1drugresistancetesting AT casadellamaria performancecomparisonofnextgenerationsequencinganalysispipelinesforhiv1drugresistancetesting AT howisonmark performancecomparisonofnextgenerationsequencinganalysispipelinesforhiv1drugresistancetesting AT coetzermia performancecomparisonofnextgenerationsequencinganalysispipelinesforhiv1drugresistancetesting AT avilariossantiago performancecomparisonofnextgenerationsequencinganalysispipelinesforhiv1drugresistancetesting AT capinarupert performancecomparisonofnextgenerationsequencinganalysispipelinesforhiv1drugresistancetesting AT mariniereric performancecomparisonofnextgenerationsequencinganalysispipelinesforhiv1drugresistancetesting AT vandomselaargary performancecomparisonofnextgenerationsequencinganalysispipelinesforhiv1drugresistancetesting AT noguerajulianmarc performancecomparisonofnextgenerationsequencinganalysispipelinesforhiv1drugresistancetesting AT kirkbydon performancecomparisonofnextgenerationsequencinganalysispipelinesforhiv1drugresistancetesting AT knaggsjeff performancecomparisonofnextgenerationsequencinganalysispipelinesforhiv1drugresistancetesting AT harriganrichard performancecomparisonofnextgenerationsequencinganalysispipelinesforhiv1drugresistancetesting AT quinonesmateumiguel performancecomparisonofnextgenerationsequencinganalysispipelinesforhiv1drugresistancetesting AT paredesroger performancecomparisonofnextgenerationsequencinganalysispipelinesforhiv1drugresistancetesting AT kantorrami performancecomparisonofnextgenerationsequencinganalysispipelinesforhiv1drugresistancetesting AT sandstrompaul performancecomparisonofnextgenerationsequencinganalysispipelinesforhiv1drugresistancetesting AT jihezhao performancecomparisonofnextgenerationsequencinganalysispipelinesforhiv1drugresistancetesting |